Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

Haematologica

Volumn 98, Issue 3, 2013, Pages 364-370

  Korfel, Agnieszka ^a   Elter, Thomas ^b   Thiel, Eckhard ^a   Hänel, Matthias ^c   Möhle, Robert ^d   Schroers, Roland ^e   Reiser, Marcel ^b   Dreyling, Martin ^f   Eucker, Jan ^a   Scholz, Christian ^a   Metzner, Bernd ^g   Röth, Alexander ^h   Birkmann, Josef ⁱ   Schlegel, Uwe ^e   Martus, Peter ^a,d   Illerhaus, Gerard ^j   Fischer, Lars ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g KLINIKUM OLDENBURG   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE; THIOTEPA; ANTINEOPLASTIC AGENT;

ADULT; AGED; AGGRESSIVE LYMPHOMA; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONFUSION; CREATININE CLEARANCE; DIARRHEA; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROSPECTIVE STUDY; RELAPSE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INDUCTION CHEMOTHERAPY; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; INFUSIONS, SPINAL; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84874534353     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.077917     Document Type: Article

References (28)

1. Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2005; 19(4):597-609.
2. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-57.
3. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009; 113(17):3896-902.
4. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-33.
5. Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23(5):1267-73.
6. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178-84.
7. Korfel A. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol. 2011;23(5):436-40.
8. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110-6.
9. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993;11(3):561-9.
10. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085-93.
11. Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol. 2006;85(1):45-50.
12. Patrij K, Reiser M, Watzel L, Pels H, Kowoll A, Herrlinger U, et al. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci. 2011;Vol. 9, ISSN 1612-3174.
13. Herrlinger U, Forschler H, Kuker W, Meyermann R, Bamberg M, Dichgans J, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci. 2004;223(2):167-78.
14. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27): 4184-90.
15. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991;77(7):1587-92.
16. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma. J Clin Oncol. 2006;24(24):3875-80.
17. Illerhaus G, Muller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147-8.
18. Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, et al. Highdose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6(3A):352-8.
19. Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant. 2005;11(2):93-100.
20. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol. 1994;12(11):2415-22.
21. Kuker W, Nagele T, Thiel E, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology. 2005;65(7): 1129-31.
22. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16(3):445-9.
23. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244.
24. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-43.
25. Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol. 2009;88(2):133-9.
26. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151-6.
27. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010; 11(11):1036-47.
28. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046-52.